Cargando…
Hybrid drug-screening strategy identifies potential SARS-CoV-2 cell-entry inhibitors targeting human transmembrane serine protease
The spread of coronavirus infectious disease (COVID-19) is associated with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which has risked public health more than any other infectious disease. Researchers around the globe use multiple approaches to identify an effective approved d...
Autores principales: | Feng, Yufei, Cheng, Xiaoning, Wu, Shuilong, Mani Saravanan, Konda, Liu, Wenxin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9091140/ https://www.ncbi.nlm.nih.gov/pubmed/35571866 http://dx.doi.org/10.1007/s11224-022-01960-w |
Ejemplares similares
-
Pharmacoinformatics-based identification of transmembrane protease serine-2 inhibitors from Morus Alba as SARS-CoV-2 cell entry inhibitors
por: Shakya, Anshul, et al.
Publicado: (2021) -
Interaction of Protein C Inhibitor with the Type II Transmembrane Serine Protease Enteropeptidase
por: Prohaska, Thomas A., et al.
Publicado: (2012) -
Potential Simultaneous Inhibitors of Angiotensin-Converting Enzyme 2 and Transmembrane Protease, Serine 2
por: Wu, Ching-Yuan, et al.
Publicado: (2020) -
Docking study of transmembrane serine protease type 2 inhibitors for the treatment of COVID-19
por: Solanki, Naishadh
Publicado: (2022) -
In-silico screening for identification of potential inhibitors against SARS-CoV-2 transmembrane serine protease 2 (TMPRSS2)
por: Barge, Sagar, et al.
Publicado: (2021)